Table 1. Individual clinical characteristics at inclusion and allergy features at first and fourth oral food challenges of patients under omalizumab and oral immunotherapy for cow’s milk allergy.
Figure 1. Study protocol illustration. After a period of inclusion, corresponding to IgE-mediated diagnosis and prognosis evaluation, omalizumab is administrated alone for 16 weeks. Oral immunotherapy with fresh cow’s milk is then initiated by oral food challenge (OFC1) in order to determine the first cumulative dose (CTD1) and then the first threshold to reach by up-dosing. OFCs were regularly performed to increase the threshold. Study outcomes were assessed after OFC4.
Figure S1. Evolution of allergy features throughout protocol.Each dot and line correspond to one patient. OFC: oral food challenge.
Table S1. Responses to satisfaction survey completed by children and their parents.